NASDAQ:MGNX MacroGenics Q2 2025 Earnings Results & Report $3.37 +0.06 (+1.81%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$3.37 0.00 (0.00%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. MacroGenics beat analyst earnings expectations but missed on revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.57 versus the -$0.59 consensus estimate, while revenue of $22.24 million fell short of the $28.06 million estimate by $5.82 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call7:00 AM ET MacroGenics EPS ResultsActual EPS-$0.57Consensus EPS -$0.59Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersMacroGenics Revenue ResultsActual Revenue$22.24 millionExpected Revenue$28.06 millionBeat/MissMissed by -$5.82 millionYoY Revenue GrowthN/AUpcoming EarningsMacroGenics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) MacroGenics Q2 2025 Earnings FAQ Did MacroGenics beat earnings estimates for Q2 2025? MacroGenics (NASDAQ:MGNX) reported earnings of -$0.57 per share for Q2 2025, beating the consensus estimate of -$0.59. The report was announced on Thursday, August 14, 2025. What was MacroGenics' revenue for Q2 2025? MacroGenics reported revenue of $22.24 million for Q2 2025, against a consensus estimate of $28.06 million. When is MacroGenics' next earnings date? MacroGenics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for MacroGenics on the company's earnings history page. MacroGenics Earnings HeadlinesMacroGenics, Inc. Announces First Patient Dosed In Phase 1 Study Of MGC030 In Patients With Advanced Solid Tumors58 minutes ago | marketscreener.comMMacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid TumorsOctober 15 at 5:32 PM | marketscreener.comMMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.October 16 at 1:00 AM | Porter & Company (Ad)MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsOctober 15 at 4:05 PM | globenewswire.comFinancial Review: Madrigal Pharmaceuticals (NASDAQ:MDGL) & MacroGenics (NASDAQ:MGNX)October 10, 2026 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) & Keros Therapeutics (NASDAQ:KROS) Head-To-Head SurveyOctober 5, 2026 | americanbankingnews.comSee More MacroGenics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MacroGenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MacroGenics and other key companies, straight to your email. Email Address About MacroGenicsMacroGenics (NASDAQ:MGNX) is a biopharmaceutical company focused on developing antibody-based therapies for cancer and other serious diseases. Based in Rockville, Maryland, the company uses its proprietary DART platform to design molecules intended to direct the immune system against diseased cells, along with technologies for modifying antibody activity and half-life. MacroGenics’ commercial products include MARGENZA (margetuximab-cmkb), an antibody approved in the United States for certain patients with HER2-positive metastatic breast cancer, and ZYNYZ (retifanlimab-dlwr), an immune checkpoint inhibitor approved for adults with metastatic or recurrent Merkel cell carcinoma. The company also maintains a pipeline of investigational therapies for oncology and autoimmune indications. Founded in 2000, MacroGenics conducts research and clinical development activities in the United States and works with international pharmaceutical partners to develop and commercialize certain products in additional markets. The company was founded by Scott Koenig, who has served as its chief executive officer and has led its development of antibody-based therapeutics.View MacroGenics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
